Literature DB >> 28870470

Poliovirus Receptor: More than a simple viral receptor.

Jonathan R Bowers1, James M Readler1, Priyanka Sharma1, Katherine J D A Excoffon2.   

Abstract

The human poliovirus receptor (PVR) is a cell surface protein with a multitude of functions in human biology. PVR was initially identified as the receptor for the human poliovirus and recent discoveries have given a greater insight into both its morphology and its function. Alternative splicing of the PVR gene results in a total of 4 alternatively spliced isoforms. Two of these isoforms lack a complete transmembrane domain and are considered soluble and block viral infection; the remaining two transmembrane isoforms differ only at their extreme C-terminal domains resulting in differential localization in epithelia and polarity of viral infection. In addition to its role as a receptor for the human poliovirus, several native biological functions have also been uncovered. PVR is an important cell adhesion protein and is involved in the transendothelial migration of leukocytes. Through its interactions with CD226 and TIGIT, transmembrane proteins found on leukocytes, PVR is a key regulator of the cell-mediated immune response. As PVR is differentially regulated in a broad spectrum of cancers, it has a strong potential for clinical use as a biomarker. PVR is also a possible target for novel cancer therapies. Utilizing its natural tropism for PVR, a genetically modified form of the live attenuated poliovirus vaccine is currently being tested for its ability to locate and destroy certain tumors. These recent studies emphasize the importance of PVR in human biology and demonstrate its utility beyond being a viral receptor protein.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD155; Human poliovirus receptor (PVR); Immunomodulation; Poliovirus

Mesh:

Substances:

Year:  2017        PMID: 28870470      PMCID: PMC5650920          DOI: 10.1016/j.virusres.2017.09.001

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  80 in total

1.  CD99 plays a major role in the migration of monocytes through endothelial junctions.

Authors:  Alan R Schenkel; Zahra Mamdouh; Xia Chen; Ronald M Liebman; William A Muller
Journal:  Nat Immunol       Date:  2002-01-14       Impact factor: 25.606

2.  1. Alternative splicing of viral receptors: A review of the diverse morphologies and physiologies of adenoviral receptors.

Authors:  Katherine J D A Excoffon; Jonathan R Bowers; Priyanka Sharma
Journal:  Recent Res Dev Virol       Date:  2014

3.  The PDZ3 domain of the cellular scaffolding protein MAGI-1 interacts with the Coxsackievirus and adenovirus receptor (CAR).

Authors:  Ran Yan; Priyanka Sharma; Abimbola O Kolawole; Sterling C T Martin; James M Readler; Poornima L N Kotha; Heather A Hostetler; Katherine J D A Excoffon
Journal:  Int J Biochem Cell Biol       Date:  2015-01-23       Impact factor: 5.085

4.  Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice.

Authors:  Tsukasa Nabekura; Kazuko Shibuya; Eri Takenaka; Hirayasu Kai; Kai Shibata; Yumi Yamashita; Kyoichi Harada; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Akira Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

5.  Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.

Authors:  Kohei Ishiyama; Hideki Ohdan; Masahiro Ohira; Hiroshi Mitsuta; Koji Arihiro; Toshimasa Asahara
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

6.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

7.  TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.

Authors:  Kristen E Pauken; E John Wherry
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

8.  UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells.

Authors:  Jiuyu Gong; Liang Fang; Rongrong Liu; Ying Wang; Jinliang Xing; Yibing Chen; Ran Zhuang; Yun Zhang; Chunmei Zhang; Angang Yang; Xudong Zhang; Boquan Jin; Lihua Chen
Journal:  Eur J Immunol       Date:  2014-10-29       Impact factor: 5.532

9.  Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.

Authors:  D J Filman; R Syed; M Chow; A J Macadam; P D Minor; J M Hogle
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

10.  The location and nature of enterovirus receptors in susceptible cells.

Authors:  J J HOLLAND; L C McLAREN
Journal:  J Exp Med       Date:  1961-08-01       Impact factor: 14.307

View more
  20 in total

1.  CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis.

Authors:  Junichi Ikeda; Chisato Ohe; Takashi Yoshida; Ryoichi Saito; Koji Tsuta; Hidefumi Kinoshita
Journal:  Oncol Lett       Date:  2022-09-28       Impact factor: 3.111

2.  CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.

Authors:  Chang Jiang; Xiaodie Qu; Li Ma; Ling Yi; Xu Cheng; Xiang Gao; Jinghui Wang; Nanying Che; Hongtao Zhang; Shucai Zhang
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 3.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

4.  Long Noncoding RNA KCNQ1OT1 is a Prognostic Biomarker and mediates CD8+ T cell exhaustion by regulating CD155 Expression in Colorectal Cancer.

Authors:  Zheng-Bin Lin; Pei Long; Zhan Zhao; Yi-Ran Zhang; Xiao-Dong Chu; Xiao-Xu Zhao; Hui Ding; Song-Wei Huan; Yun-Long Pan; Jing-Hua Pan
Journal:  Int J Biol Sci       Date:  2021-04-22       Impact factor: 6.580

5.  Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.

Authors:  Bin Ma; Xiangguo Duan; Qiunan Zhou; Juanxi Liu; Xiaojuan Yang; Dong Zhang; Shaoqi Yang; Yong Du; Hai Li; Chunxia Su
Journal:  J Cell Mol Med       Date:  2019-05-14       Impact factor: 5.310

Review 6.  The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.

Authors:  Hao-Fan Wang; Sha-Sha Wang; Ya-Jie Tang; Yu Chen; Min Zheng; Ya-Ling Tang; Xin-Hua Liang
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

Review 7.  CD155: A Multi-Functional Molecule in Tumor Progression.

Authors:  Rosa Molfetta; Beatrice Zitti; Mario Lecce; Nadia Domenica Milito; Helena Stabile; Cinzia Fionda; Marco Cippitelli; Angela Gismondi; Angela Santoni; Rossella Paolini
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

8.  Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Authors:  Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen
Journal:  Biomolecules       Date:  2021-05-10

9.  A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.

Authors:  Shiran Hoogi; Vasyl Eisenberg; Shimrit Mayer; Astar Shamul; Tilda Barliya; Cyrille J Cohen
Journal:  J Immunother Cancer       Date:  2019-09-09       Impact factor: 13.751

Review 10.  NK Cell-Based Immune Checkpoint Inhibition.

Authors:  Muhammad Khan; Sumbal Arooj; Hua Wang
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.